Laura A. Leber
Laura A. Leber was named as Vice President, Corporate Communications for the biotech compeny Genentech.
PR Week described Leber as one of the Top 50 women in the PR industry. "In a career spanning 15 years, Laura Leber has counseled most of the leading pharmaceutical companies including Procter & Gamble, Smith Kline & French, Beecham Laboratories, Searle and Bayer. Recently promoted to VP, corporate communications, she has developed the Identity Building Program to manage corporate issues such as the Department of Justice settlement, University of California patent infringement lawsuit and issues related to the breast cancer drug Herceptin. Previously, she worked at both Fleishman Hillard and Hill&Knowlton with their major healthcare clients. She is currently chair of the Communications Committee of the Biotechnology Industry Organization," Rebecca Flass wrote.  (Sub req'd).
In March 2000 PR Week that Laura A. Leber, the Vice president, corporate communications for Genentech described her as the architect of early PR on Herecptin. "With the promotion of Herceptin, a treatment for breast cancer, Leber pioneered the company’s advocate-relations efforts by creating the first program designed to provide patients access to experimental drugs."  (Sub req'd)
- Rebecca Flass, "The 50 most powerful women in PR - Women outnumber men in the PR field, but there are still few at the very top", PR Week, August 9, 1999.
- Michelle Foster, "Who’s who in corporate healthcare PR, PR Week"", March 6, 2000. (Sub req'd).
|This article is a stub. You can help by expanding it.|